Intellia Therapeutics (NTLA) EBITDA (2015 - 2026)

Intellia Therapeutics (NTLA) has reported EBITDA for 12 consecutive years, with -$100.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA rose 16.78% year-over-year to -$100.5 million; the TTM figure through Mar 2026 stood at -$420.7 million (up 22.24% YoY), while the FY2025 annual figure was -$441.0 million, up 17.46% from the prior year.
• EBITDA eased to -$100.5 million in Q1 2026 per NTLA's latest filing, from -$98.7 million in the prior quarter.
• Across five years, EBITDA topped out at -$98.3 million in Q2 2022 and bottomed at -$144.8 million in Q3 2024.
• Historically, EBITDA has averaged -$120.5 million across 5 years, with a median of -$114.0 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA plunged 210.71% — and 2025, when it advanced 27.66%.
• Intellia Therapeutics' EBITDA stood at -$110.1 million in 2022, then fell by 27.07% to -$139.9 million in 2023, then increased by 2.46% to -$136.4 million in 2024, then increased by 27.66% to -$98.7 million in 2025, then decreased by 1.85% to -$100.5 million in 2026.
• Business Quant data shows NTLA's EBITDA at -$100.5 million in Q1 2026, -$98.7 million in Q4 2025, and -$111.5 million in Q3 2025.